As a highly selective small-molecule inhibitor of FABP4, BMS309403 is an orally active agent against atherosclerosis and type 2 diabetes in animal models.25 To determine whether inhibiting FABP4 may possess a renal protective effect, we examined the effect of BMS309403 on pathological changes and renal function in I/R-induced AKI. Here, FABP4 is linked to atherosclerosis.